General Information of Drug (ID: DM9RW6H)

Drug Name
JNJ-56136379 Drug Info
Synonyms JNJ-6379
Indication
Disease Entry ICD 11 Status REF
Hepatitis B 1E51 Phase 2 [1]
Cross-matching ID
PubChem CID
121294984
TTD Drug ID
DM9RW6H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABI-H2158 DM6X70G Hepatitis B 1E51 Phase 2 [3]
ABI-H0731 DMX1KDM Hepatitis B 1E51 Phase 2 [4]
ABI-H3733 DM4TN6W Hepatitis B 1E51 Phase 1 [3]
EDP-514 DM8KRA3 Chronic HBV infection 1E51.0Z Phase 1 [5]
RG7907 DMKVIS5 Hepatitis B 1E51 Phase 1 [6]
ZM-H1505R DMX6AJ8 Hepatitis B 1E51 Phase 1 [7]
A204 DMF1LYP Hepatitis B virus infection 1E51.0 Phase 1 [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis B virus Capsid protein (HBV C) TTM42UJ CAPSD_HBVD3 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03361956) An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection. U.S. National Institutes of Health.
2 JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
3 Clinical pipeline report, company report or official report of Assembly Biosciences.
4 Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
5 Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
6 Clinical pipeline report, company report or official report of Roche.
7 Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma.
8 Clinical pipeline report, company report or official report of Klus Pharma